Journal of International Oncology››2016,Vol. 43››Issue (1): 39-41.doi:10.3760/cma.j.issn.1673-422X.2016.01.011
Previous ArticlesNext Articles
Sun Xiaoliang, Lu Yao, Yang Meng, Huang Linping
Received:
2015-05-07Online:
2016-01-08Published:
2015-12-03Contact:
Huang Linping E-mail:hlpsurg@sina.comSun Xiaoliang, Lu Yao, Yang Meng, Huang Linping. Treatment of papillary thyroid microcarcinoma[J]. Journal of International Oncology, 2016, 43(1): 39-41.
[1] Brown SR, Lee S, Brown TA, et al. Effect of race on thyroid cancer care in an equal access healthcare system[J]. Am J Surg, 2010, 199(5): 685-689. DOI:10.1016/j.amjsurg.2010.01.020. [2] Edge SB, Compton CC. The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM[J]. Ann Surg Oncol, 2010, 17(6): 1471-1474. DOI:10.1245/s10434-010-0985-4. [3] Slijepcevic N, Zivaljevic V, Marinkovic J, et al. Retrospective evaluation of the incidental finding of 403 papillary thyroid microcarcinomas in 2466 patients undergoing thyroid surgery for presumed benign thyroid disease[J]. BMC Cancer, 2015, 15(1): 330. DOI:10.1186/s1288501513524. [4] Lombardi CP, Bellantone R, De Crea C, et al. Papillary thyroid microcarcinoma: extrathyroidal extension, lymph node metastases, and risk factors for recurrence in a high prevalence of goiter area[J]. World J Surg, 2010, 34(6): 1214-1221. DOI:10.1007/s00268-009-0375-x. [5] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015[J]. CA Cancer J Clin, 2015, 65(1): 5-29. DOI:10.3322/caac.21254. [6] Ito Y, Miyauchi A, Inoue H, et al. An observational trial for papillary thyroid microcarcinoma in Japanese patients[J]. World J Surg, 2010, 34(1): 2835. DOI:10.1007/s0026800903030. [7] Takami H, Ito Y, Okamoto T, et al. Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons[J]. World J Surg, 2011, 35(1): 111121. DOI:10.1007/s00268-010-0832-6. [8] Wu AW, Nguyen C, Wang MB. What is the best treatment for papillary thyroid microcarcinoma?[J]. Laryngoscope, 2011, 121(9): 1828-1829. DOI:10.1002/lary.22033. [9] Chow SM, Law SC, Chan JK, et al. Papillary microcarcinoma of the thyroidPrognostic significance of lymph node metastasis and multifocality[J]. Cancer, 2003, 98(1): 31-40. DOI:10.1002/cncr.11442. [10] Hay ID, Grant CS, Van Heerden JA, et al. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50year period[J]. Surgery, 1992, 112(6): 1139-1146. [11] Hay ID, Hutchinson ME, GonzalezLosada T, et al. Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60year period[J]. Surgery, 2008, 144(6): 980-987. DOI:10.1016/j.surg.2008.08.035. [12] So YK, Son YI, Hong SD, et al. Subclinical lymph node metastasis in papillary thyroid microcarcinoma: a study of 551 resections[J]. Surgery, 2010, 148(3): 526-531. DOI:10.1016/j.surg.2010.01.003. [13] Tae K, Ji YB, Cho SH, et al. Initial experience with a gasless unilateral axillobreast or axillary approach endoscopic thyroidectomy for papillary thyroid microcarcinoma: comparison with conventional open thyroidectomy[J]. Surg Laparosc Endosc Percutan Tech, 2011, 21(3): 162-169. DOI:10.1097/SLE.0b013e318218d1a4. [14] Gao W, Liu L, Ye G, et al. Application of minimally invasive videoassisted technique in papillary thyroid microcarcinoma[J]. Surg Laparosc Endosc Percutan Tech, 2013, 23(5): 468-473. DOI:10.1097/SLE.0b013e318274b611. [15] Lee S, Ryu HR, Park JH, et al. Early surgical outcomes comparison between robotic and conventional open thyroid surgery for papillary thyroid microcarcinoma[J]. Surgery, 2012, 151(5): 724-730. DOI:10.1016/j.surg.2011.12.013. [16] Buffet C, Golmard JL, Hoang C, et al. Scoring system for predicting recurrences in patients with papillary thyroid microcarcinoma[J]. Eur J Endocrinol, 2012, 167(2): 267-275. DOI:10.1530/EJE120105. [17] Pisanu A, Reccia I, Nardello O, et al. Risk factors for nodal metastasis and recurrence among patients with papillary thyroid microcarcinoma: differences in clinical relevance between nonincidental and incidental tumors[J]. World J Surg, 2009, 33(3): 460-468. DOI:10.1007/s00268-008-9870-8. |
[1] | Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei.Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma: a real-world clinical study[J]. Journal of International Oncology, 2024, 51(6): 326-331. |
[2] | Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337. |
[3] | Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua.Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy[J]. Journal of International Oncology, 2024, 51(5): 257-266. |
[4] | Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279. |
[5] | Liu Pingping, He Xuefang, Zhang Yi, Yang Xu, Zhang Shanshan, Ji Yifei.Risk factors of postoperative recurrence in patients with primary brain glioma and prediction model construction[J]. Journal of International Oncology, 2024, 51(4): 193-197. |
[6] | Wan Fang, Yang Gang, Li Rui, Wan Qijing.Expression levels and clinical significance of serum miR-497 and miR-383 in patients with esophageal cancer[J]. Journal of International Oncology, 2024, 51(4): 204-209. |
[7] | Yao Yixin, Shen Yulin.Predictive value of serum SOCS3 and TXNIP levels for the prognosis of patients with hepatocellular carcinoma treated with TACE[J]. Journal of International Oncology, 2024, 51(4): 217-222. |
[8] | Sun Weiwei, Yao Xuemin, Wang Pengjian, Wang Jing, Jia Jinghao.Exploration of prognostic factors and nomogram construction for advanced non-small cell lung cancer treated with immunotherapy based on hematologic indexes[J]. Journal of International Oncology, 2024, 51(3): 143-150. |
[9] | Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan.Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer[J]. Journal of International Oncology, 2024, 51(3): 175-180. |
[10] | Peng Qin, Cai Yuting, Wang Wei.Advances on KPNA2 in liver cancer[J]. Journal of International Oncology, 2024, 51(3): 181-185. |
[11] | Chen Boguang, Wang Sugui, Zhang Yongjie.Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer[J]. Journal of International Oncology, 2024, 51(2): 73-82. |
[12] | Jin Xudong, Chen Zhongjian, Mao Weimin.Research progress on the role of MTAP in malignant mesothelioma[J]. Journal of International Oncology, 2024, 51(2): 99-104. |
[13] | Huang Zhen, Chen Yongshun.Research progress of circulating tumor DNA in the diagnosis and treatment of hepatocellular carcinoma[J]. Journal of International Oncology, 2024, 51(1): 59-64. |
[14] | Wang Xiao, Li Ying, Luo Yujie, Jin Shu.Study on the prognostic value of serological indicators for nasopharyngeal carcinoma based on nomogram model[J]. Journal of International Oncology, 2023, 50(8): 463-469. |
[15] | Liu Debao, Sun Ziwen, Lu Shoutang, Xu Haidong.Expression and clinical significance of ASB6 in colorectal cancer tissues[J]. Journal of International Oncology, 2023, 50(8): 470-474. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||